# Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys

> **NCT00001984** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 5 (actual)

## Conditions studied

- Graft Rejection
- Kidney Disease

## Interventions

- **DRUG:** Alemtuzumab and DSG

## Key facts

- **NCT ID:** NCT00001984
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2016-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001984, "Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00001984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*